|
| Status |
Public on Mar 16, 2015 |
| Title |
SMO variants explain the majority of drug resistance in basal cell carcinoma |
| Organism |
Homo sapiens |
| Experiment type |
Other
Expression profiling by high throughput sequencing
|
| Summary |
This SuperSeries is composed of the SubSeries listed below.
|
| |
|
| Overall design |
Refer to individual Series
|
| |
|
| Citation(s) |
25759020 |
| Submission date |
Jun 10, 2014 |
| Last update date |
May 15, 2019 |
| Contact name |
Jiang Li |
| E-mail(s) |
jiangli@stanford.edu
|
| Phone |
6507258839
|
| Organization name |
Stanford University
|
| Department |
Dermatology
|
| Lab |
Tony Oro
|
| Street address |
269 Campus Drive, Stanford University
|
| City |
Stanford |
| State/province |
CA |
| ZIP/Postal code |
94305 |
| Country |
USA |
| |
|
| Platforms (2) |
| GPL15520 |
Illumina MiSeq (Homo sapiens) |
| GPL16791 |
Illumina HiSeq 2500 (Homo sapiens) |
|
| Samples (107)
|
|
| This SuperSeries is composed of the following SubSeries: |
| GSE58374 |
SMO variants explain the majority of drug resistance in basal cell carcinoma [exome-seq] |
| GSE58375 |
SMO variants explain the majority of drug resistance in basal cell carcinoma [RNA-Seq] |
| GSE58376 |
SMO variants explain the majority of drug resistance in basal cell carcinoma [Target Sequencing] |
|
| Relations |
| BioProject |
PRJNA252374 |
Less...
More...